Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs. Issue 1 (1st January 2019)

• Record Type: Journal Article
• Authors: Solà-Morales, Oriol; Volmer, Timm; Mantovani, Lorenzo
• Is Part Of: Journal of market access & health policy. Volume 7:Issue 1(2019)
• Publication Date: 2019-01-01
• Subjects: Oncology -- patient access -- HTA -- reimbursement -- surrogate endpoint -- Health Related Quality of Life (HRQoL); Medical policy -- Periodicals; Medical policy -- Economic aspects -- Periodicals; International trade -- Environmental aspects -- Periodicals; Health Policy -- economics; Technology Assessment, Biomedical; Marketing of Health Services; International trade -- Environmental aspects; Medical policy; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 362.1
• DOI: 10.1080/20016689.2018.1562861
• Languages: English
• ISSNs: 2001-6689

Abstract

ABSTRACT: Reimbursement decisions on new oncology drugs are now often made while uncertainty remains about a drug's risk–benefit profile. One consequence of this is a delay in patient access to valuable new medicines. We share our perspectives on strategies to mitigate sources of uncertainty in the health technology assessment process. These include flexible approaches for evaluating the additional benefit, such as better use of surrogate endpoints and health-related quality of life data, and renewed research efforts to define the optimal target population and generate real-world evidence post-authorisation.